Vaccitech induces T cells and antibodies to treat and prevent disease

Learn More

Learn more Vaccitech induces T cells and antibodies to treat and
prevent disease
Learn more Human Papillomavirus causes nearly all cases of cervical cancer Learn more Chronic hepatitis B affects an estimated 257 million
people worldwide
Learn more SARS-CoV-2 has caused a worldwide pandemic of respiratory illness, commonly referred to as COVID-19

life at vaccitech

Our Mission

Image: NIAID

Treating and Preventing Disease

We develop T cell immunotherapeutic products and vaccines to improve global health

Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the most prestigious vaccine research centres in the world.

Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients Oxford, UK - Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer,...
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
European Medicines Agency recommends conditional marketing authorisation to ChAdOx1 coronavirus vaccine Oxford, UK - Vaccitech Ltd announces that the European Medicines Agency (EMA) has today recommended the conditional marketing authorisation of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford...
European Medicines Agency recommends conditional marketing authorisation to ChAdOx1 coronavirus vaccine
Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine Oxford, UK - Vaccitech Ltd announces that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus...
Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
First peer-reviewed results of Phase 3 human trials of Oxford vaccine demonstrate efficacy Oxford, UK - Vaccitech’s scientific founders at University of Oxford and Astrazeneca announce the first peer-reviewed publication of Phase 3 data from studies of a vaccine against the coronavirus in...
First peer-reviewed results of Phase 3 human trials of Oxford vaccine demonstrate efficacy
Vaccitech Chief Scientific Officer Dr. Thomas Evans on COVID-19 vaccination  In an interview with Sky News, Vaccitech Chief Scientific Officer, Dr. Thomas Evans, discusses the regulatory and public health aspects of Emergency Use Authorisation of COVID-19 vaccines. The interview aired on...
Vaccitech Chief Scientific Officer Dr. Thomas Evans on COVID-19 vaccination
Vaccitech Co-Founder Professor Adrian Hill on Developing a Covid-19 Vaccine Following the news that AstraZeneca, the University of Oxford, and Vaccitech's vaccine for COVID-19 is highly effective and safe, Vaccitech co-founder Professor Adrian Hill talked to Tom Hulme, General Partner...
Vaccitech Co-Founder Professor Adrian Hill on Developing a Covid-19 Vaccine

OUR APPROACH

Teaching the immune system to confront deadly infections

Traditional vaccine technology creates a pronounced antibody response to the infectious agent. Vaccitech’s platform is able to also induce potent and durable T cell responses from the cellular arm of the immune system.